Ocugen, Inc. (NASDAQ:OCGN) Shares Purchased by Barclays PLC

Barclays PLC grew its position in shares of Ocugen, Inc. (NASDAQ:OCGN) by 104.3% during the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 581,087 shares of the company’s stock after purchasing an additional 296,654 shares during the period. Barclays PLC owned approximately 0.20% of Ocugen worth $577,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of the company. Xponance Inc. acquired a new position in Ocugen during the 2nd quarter worth about $25,000. Victory Capital Management Inc. acquired a new stake in shares of Ocugen during the second quarter worth about $51,000. Daiwa Securities Group Inc. purchased a new position in shares of Ocugen in the second quarter valued at approximately $67,000. E Fund Management Co. Ltd. acquired a new position in shares of Ocugen in the second quarter valued at approximately $75,000. Finally, SG Americas Securities LLC purchased a new stake in Ocugen during the 3rd quarter worth approximately $87,000. 10.27% of the stock is currently owned by hedge funds and other institutional investors.

Ocugen Trading Down 0.4 %

NASDAQ OCGN opened at $0.81 on Thursday. Ocugen, Inc. has a 52 week low of $0.49 and a 52 week high of $2.11. The firm has a 50 day moving average of $0.90 and a two-hundred day moving average of $1.16. The company has a quick ratio of 2.58, a current ratio of 2.58 and a debt-to-equity ratio of 0.04. The stock has a market capitalization of $234.51 million, a PE ratio of -4.47 and a beta of 3.82.

Wall Street Analysts Forecast Growth

OCGN has been the subject of several recent research reports. Maxim Group assumed coverage on shares of Ocugen in a research report on Tuesday, October 15th. They issued a “buy” rating and a $4.00 price target for the company. Chardan Capital reiterated a “buy” rating and issued a $6.00 target price on shares of Ocugen in a report on Monday, November 18th. Finally, HC Wainwright restated a “buy” rating and set a $7.00 price target on shares of Ocugen in a report on Monday, November 11th.

About Ocugen

Ocugen, Inc, a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients’ health. The company’s pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease.